Pulmonary Toxicity Recurring after a Six Week Course of Busulfan Therapy and after Subsequent Therapy with Uracil Mustard

Hankins, Daniel; Sanders, Scott; MacDonald, Frank M.; Drage, Charles W.

doi:10.1378/chest.73.3.415

Cited by 29 publications

(10 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Al-Hashmi et al (2011) examined the tissues shortly after treatment, while we examined 1-2 months later. Bu is well known for lung injury shortly after the clinical treatment (Soble and Perry, 1977;Hankins et al, 1978;Schallier et al, 1983;Vergnon et al, 1988). However, the literature is lacking a clear understanding of the mechanisms by which Bu induces lung impairment, because there are no animal models of Bu-induced pulmonary toxicity.…”

Section: Discussionmentioning

confidence: 99%

Accelerated ovarian aging in mice by treatment of busulfan and cyclophosphamide

Jiang

Zhao

et al. 2013

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Busulfan/cyclophosphamide (Bu/Cy) conditioning regimen has been widely used to treat cancer patients, while their effects on major internal organs in females are not fully understood. We treated female mice with Bu/Cy, and examined the histopathology of major internal organs on Day 30 after the treatment. The results show that Bu/Cy treatment affected the ovaries most extensively, while it had less effect on the spleen, lungs, and kidneys, and no effect on the heart, liver, stomach, and pancreas. To better understand the effect of Bu/Cy on the ovaries, we counted follicles, and determined the levels of ovarian steroids. The Bu/Cy-treated mice showed a reduction of primordial and primary follicles (P<0.01) on Day 30 and a marked loss of follicles at all developmental stages (P<0.01) on Day 60. Plasma levels of estradiol and progesterone in Bu/Cy-treated mice decreased by 43.9% and 61.4%, respectively. Thus, there was a gradual process of follicle loss and low estradiol in Bu/Cy-treated mice; this is a profile similar to what is found in women with premature ovarian failure (POF). The Bu/Cy-treated mice may serve as a useful animal model to study the dynamics of follicle loss in women undergoing POF.

show abstract

Section: Discussionmentioning

confidence: 99%

Accelerated ovarian aging in mice by treatment of busulfan and cyclophosphamide

Jiang

Zhao

et al. 2013

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

show abstract

“…However, a recent report of a patient whose symptoms began within six weeks of initiating therapy shortens this interval. 15 I have seen a similar patients whose symptomatic onset began acutely six weeks after taking the drug (Fig. 1).…”

mentioning

confidence: 74%

“…Since Oliner's report in 1961, many cases have subsequently been recognized. [5][6][7][8][9][10][11][12][13][14][15] It is still the initial drug of choice in chronic myelogenous leukemia. The incidence of busulfan lung in those taking the medication over many years is not really known, but two separate reports each give an estimate of 8 percent.…”

mentioning

confidence: 99%

Chemotherapeutic Drug-Induced Pulmonary Disease

Rosenow¹

1980

Semin Respir Crit Care Med

View full text Add to dashboard Cite

“…Symptomatic pulmonary injury is estimated to occur in <5% of patients treated with busulfan [13, 18, 19]. Subclinical lung damage may develop in a considerably higher number of those exposed to the drug.…”

Section: Drug-induced Lung Injurymentioning

confidence: 99%

Noninfectious Lung Disease in the Immunocompromised Host

Crawford¹

1999

Respiration

View full text Add to dashboard Cite

Patients with compromised immune function suffer a wide variety of lung insults. Infections are the most common causes of both acute and chronic lung diseases, but many noninfectious conditions affect the lungs. The clinical presentation of these noninfectious conditions often mimic infections, thus causing diagnostic dilemmas. The spectrum of noninfectious lung injury and response in the immunosuppressed host includes interstitial edema, interstitial fibrosis, diffuse idiopathic pneumonia, acute respiratory distress syndrome, and obliterative bronchiolitis. Alveolar hemorrhage may complicate any of these conditions. Lung injury in the immunosuppressed host is associated with a diversity of etiologies: sepsis, irradiation, graft rejection, reperfusion injury, graft-versus-host disease, and chemotherapeutic agents and other drug reactions. These injuries most often present as diffuse pulmonary infiltrates on chest radiograph. Establishing a specific diagnosis and etiology for the injury is often problematic. From a pragmatic standpoint, excluding the possibility of infection is the principal aim of diagnostic testing.

show abstract

Pulmonary Toxicity Recurring after a Six Week Course of Busulfan Therapy and after Subsequent Therapy with Uracil Mustard

Cited by 29 publications

References 6 publications

Accelerated ovarian aging in mice by treatment of busulfan and cyclophosphamide

Accelerated ovarian aging in mice by treatment of busulfan and cyclophosphamide

Chemotherapeutic Drug-Induced Pulmonary Disease

Noninfectious Lung Disease in the Immunocompromised Host

Contact Info

Product

Resources

About